Impact of diabetes mellitus on angiographic and clinical outcomes after early generation drug-eluting stent implantation

References

• Kumar R, Lee TT, Jeremias A et al. Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Am. J. Cardiol. 100(8), 1187–1191 (2007).
   PubMedGoogle Scholar
• Zahn R, Hamm CW, Schneider S et al. German Cypher Stent Registry. Predictors of death or myocardial infarction during follow-up after coronary stenting with the sirolimus-eluting stent. Results from the prospective multicenter German Cypher Stent Registry. Am. Heart J. 152(6), 1146–1152 (2006).
   PubMedGoogle Scholar
• Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P. Efficacy of drug-eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials. Heart 92(5), 650–657 (2006).
   PubMedGoogle Scholar
• Billinger M, Räber L, Hitz S et al. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents. Am. Heart J. 163(5), 876–886.e2 (2012).
   PubMedGoogle Scholar
• Räber L, Wohlwend L, Wigger M et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization late trial. Circulation 123(24), 2819–2928, 6 p following 2828 (2011).
   PubMed Web of Science ®Google Scholar
• Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J. Am. Coll. Cardiol. 49(6), 643–656 (2007).
   PubMed Web of Science ®Google Scholar
• Lee TT, Feinberg L, Baim DS et al. Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am. J. Cardiol. 98(6), 718–721 (2006).
   PubMedGoogle Scholar
• Kastrati A, Dibra A, Mehilli J et al. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 113(19), 2293–2300 (2006).
   PubMed Web of Science ®Google Scholar
• Zahn R, Hamm CW, Schneider S et al. German Cypher Stent Registry. Coronary stenting with the sirolimus-eluting stent in clinical practice: final results from the prospective multicenter German Cypher Stent Registry. J. Interv. Cardiol. 23(1), 18–25 (2010).
   PubMedGoogle Scholar
• Yang TH, Park SW, Hong MK et al. Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. Am. J. Cardiol. 96(10), 1389–1392 (2005).
   PubMedGoogle Scholar
• Lee SW, Park SW, Kim YH et al. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus. J. Am. Coll. Cardiol. 52(9), 727–733 (2008).
   PubMedGoogle Scholar
• Stone GW, Kedhi E, Kereiakes DJ et al. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 124(8), 893–900 (2011).
   PubMed Web of Science ®Google Scholar
• Palmerini T, Dangas G, Mehran R et al. Predictors and implications of stent thrombosis in non-ST-segment elevation acute coronary syndromes: the ACUITY Trial. Circ. Cardiovasc. Interv. 4(6), 577–584 (2011).
   PubMed Web of Science ®Google Scholar
• Wenaweser P, Daemen J, Zwahlen M et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52(14), 1134–1140 (2008).
   PubMed Web of Science ®Google Scholar
• Kimura T, Morimoto T, Nakagawa Y et al.; j-Cypher Registry Investigators. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 125(4), 584–591 (2012).
   PubMed Web of Science ®Google Scholar
• de Boer SP, Lenzen MJ, Oemrawsingh RM et al. Evaluating the ‘all-comers’ design: a comparison of participants in two ‘all-comers’ PCI trials with non-participants. Eur. Heart J. 32(17), 2161–2167 (2011).
   PubMedGoogle Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study G. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med 358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study G. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med. 358(24), 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. Eur. Heart J. 32(22), 2748–2757 (2011).
   PubMed Web of Science ®Google Scholar
• Nakazawa G, Finn AV, Vorpahl M, Ladich ER, Kolodgie FD, Virmani R. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus- and paclitaxel-eluting stents. J. Am. Coll. Cardiol. 57(4), 390–398 (2011).
   PubMed Web of Science ®Google Scholar
• Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J. Am. Coll. Cardiol. 56(23), 1897–1907 (2010).
   PubMed Web of Science ®Google Scholar